Literature DB >> 31482239

Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial.

Atsushi Mizokami1, Go Kimura2, Yasuhisa Fujii3, Shiro Hinotsu4, Kouji Izumi5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31482239     DOI： 10.1007/s10147-019-01518-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  8 in total

1.  Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients.

Authors:  Kouji Izumi; Yoshifumi Kadono; Takashi Shima; Hiroyuki Konaka; Atsushi Mizokami; Eitetsu Koh; Mikio Namiki
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

2.  Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Matthew Smith; Chris Parker; Fred Saad; Kurt Miller; Bertrand Tombal; Quan Sing Ng; Martin Boegemann; Vsevolod Matveev; Josep Maria Piulats; Luis Eduardo Zucca; Oleg Karyakin; Go Kimura; Nobuaki Matsubara; William Carlos Nahas; Franco Nolè; Eli Rosenbaum; Axel Heidenreich; Yoshiyuki Kakehi; Amily Zhang; Heiko Krissel; Michael Teufel; Junwu Shen; Volker Wagner; Celestia Higano
Journal:  Lancet Oncol       Date:  2019-02-06       Impact factor: 41.316

3.  Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

Authors:  Mari I Suominen; Katja M Fagerlund; Jukka P Rissanen; Yvonne M Konkol; Jukka P Morko; ZhiQi Peng; Esa J Alhoniemi; Salla K Laine; Eva Corey; Dominik Mumberg; Karl Ziegelbauer; Sanna-Maria Käkönen; Jussi M Halleen; Robert L Vessella; Arne Scholz
Journal:  Clin Cancer Res       Date:  2017-03-31       Impact factor: 12.531

4.  Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience.

Authors:  Alessandro Sciarra; Vincenzo Gentile; Susanna Cattarino; Alessandro Gentilucci; Andrea Alfarone; Giuseppe D'Eramo; Stefano Salciccia
Journal:  Int J Urol       Date:  2014-09-03       Impact factor: 3.369

5.  Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

Authors:  Christopher J Logothetis; Ethan Basch; Arturo Molina; Karim Fizazi; Scott A North; Kim N Chi; Robert J Jones; Oscar B Goodman; Paul N Mainwaring; Cora N Sternberg; Eleni Efstathiou; Dennis D Gagnon; Margaret Rothman; Yanni Hao; Cameron S Liu; Thian S Kheoh; Christopher M Haqq; Howard I Scher; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-11-09       Impact factor: 41.316

6.  Low free testosterone predicts frailty in older men: the health in men study.

Authors:  Zoë Hyde; Leon Flicker; Osvaldo P Almeida; Graeme J Hankey; Kieran A McCaul; S A Paul Chubb; Bu B Yeap
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

Review 7.  Estrogens as regulators of bone health in men.

Authors:  Liesbeth Vandenput; Claes Ohlsson
Journal:  Nat Rev Endocrinol       Date:  2009-06-16       Impact factor: 43.330

8.  A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.

Authors:  Ruth E Langley; Howard G Kynaston; Abdulla A Alhasso; Trinh Duong; Edgar M Paez; Gordana Jovic; Christopher D Scrase; Andrew Robertson; Fay Cafferty; Andrew Welland; Robin Carpenter; Lesley Honeyfield; Richard L Abel; Michael Stone; Mahesh K B Parmar; Paul D Abel
Journal:  Eur Urol       Date:  2015-12-17       Impact factor: 20.096
  8 in total
  3 in total

1.  Risk Scoring System for Ra-223 Discontinuation and Its Effect on Prognosis: A Retrospective Study.

Authors:  Hitoshi Ito; Hiroshi Yaegashi; Yoshiyuki Okada; Takafumi Shimada; Toshihide Yamaoka; Kazutoshi Okubo; Takashi Sakamoto; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2021-07-03

2.  Appropriate Patient Status for Ra-223 Treatment in the Treatment Sequence for Castration-resistant Prostate Cancer.

Authors:  Hitoshi Ito; Hiroshi Yaegashi; Yoshiyuki Okada; Takafumi Shimada; Toshihide Yamaoka; Kazutoshi Okubo; Takashi Sakamoto; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2022-07-03

3.  Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.

Authors:  Kohei Hashimoto; Yasuhide Miyoshi; Tetsuya Shindo; Masakazu Hori; Yasumasa Tsuboi; Ko Kobayashi; Fumimasa Fukuta; Toshiaki Tanaka; Shintaro Miyamoto; Takeshi Maehana; Manabu Okada; Naotaka Nishiyama; Masahiro Yanase; Ryuichi Kato; Hiroshi Hotta; Yasuharu Kunishima; Atsushi Takahashi; Shiro Hinotsu; Koh-Ichi Sakata; Hiroshi Kitamura; Hiroji Uemura; Naoya Masumori
Journal:  Cancer Med       Date:  2020-09-22       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.